BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12939712)

  • 1. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab.
    Dillman RO
    Semin Oncol; 2003 Aug; 30(4):434-47. PubMed ID: 12939712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
    Tobinai K
    Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
    Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of antibody therapy in B-cell non-Hodgkin's lymphoma.
    Wannesson L; Ghielmini M
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S5-12. PubMed ID: 14556670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    McLaughlin P; Grillo-López AJ; Link BK; Levy R; Czuczman MS; Williams ME; Heyman MR; Bence-Bruckler I; White CA; Cabanillas F; Jain V; Ho AD; Lister J; Wey K; Shen D; Dallaire BK
    J Clin Oncol; 1998 Aug; 16(8):2825-33. PubMed ID: 9704735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in immunotherapy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Ruan J; Coleman M
    Curr Oncol Rep; 2005 Sep; 7(5):364-71. PubMed ID: 16091197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
    Smith MR; Jin F; Joshi I
    Mol Cancer Ther; 2004 Dec; 3(12):1693-9. PubMed ID: 15634664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
    Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
    J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
    Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
    Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
    Leonard JP
    Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
    Smith MR; Joshi I; Jin F; Obasaju C
    BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4. Antibody therapy for malignant lymphoma.
    Tobinai K
    Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.